Utilization of angiotensin receptor blockers (ARBs) in Canada (Q20-02)
- In 2018/19, Health Canada, the US FDA, and other regulatory agencies issued recalls of N-nitrosodimethylamine (NDMA)- and N-nitrosodiethylamine (NDEA)-contaminated angiotensin receptor blockers (ARBs).
- Despite timely dissemination of these safety communications, little is known about how prescribers and patients responded to the notices.
AIMS OF THE STUDY
To describe and compare ARB utilization before versus after drug safety communications were issued in Canada, and to examine the characteristics of patients who completely discontinued ARBs after the communications.